Posts by: Alice Melao

News

Verona Pharma’s investigational agent RPL554 will be named ensifentrine, the company announced. The “-fentrine” stem in the International Nonproprietary Names (INN) Programme indicates recognition from the World Health Organization (WHO) ... Read more

November 13, 2018November 13, 2018

FDA Approves Yupelri as New Treatment for Adults with COPD

News

Theravance Biopharma and Mylan announced that the U.S. Food and Drug Administration (FDA) approved their New Drug Application (NDA) for revefenacin (TD-4208) as a maintenance treatment for chronic obstructive pulmonary ... Read more

October 9, 2018October 9, 2018

VA Researchers Working on 3D-Printed Artificial Lung for Patients with COPD, Other Pulmonary Diseases

News

A fully functional 3D-printed artificial lung may someday help people with serious pulmonary illnesses, such as chronic obstructive pulmonary disease (COPD). A Department of Veterans Affairs (VA) research team, in ... Read more

September 7, 2018September 7, 2018

Two Phase 2 Trials Demonstrate RPL554 Has Potential to Enhance Bronchodilators’ Efficacy in COPD

News

The addition of Verona Pharma’s investigational agent RPL554 to standard short- and long-acting bronchodilators offers greater clinical benefits to patients with chronic obstructive pulmonary disease (COPD). Results of two ... Read more

August 24, 2018August 24, 2018

Bevespi Aerosphere Shows Similar Effectiveness as Anoro Elipta in COPD Study

News

AstraZeneca’s Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) has been shown to have similar therapeutic activity in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) as GlaxoSmithKline’s approved therapy ... Read more

July 17, 2018July 17, 2018

Low, Moderate Psychological Distress Increases Risk of COPD, Other Diseases, Study Shows

News

Psychological distress, even at low or moderate levels, increases the risk of arthritis, cardiovascular disease, and chronic obstructive pulmonary disease (COPD), researchers have found. This finding was reported in ... Read more

June 29, 2018June 29, 2018

New UK Study Recruiting Participants for Evaluation of Early COPD Risk Factors

News

A new clinical trial being conducted in the United Kingdom is recruiting participants to study the early stages of chronic obstructive pulmonary disease (COPD), and identify people at risk ... Read more

June 26, 2018June 26, 2018

Synairgen’s Antiviral Therapy SNG001 Proven Safe for COPD Patients in Phase 2 Trial

News

Preliminary results from a Phase 2 trial show that Synairgen’s investigative therapy SNG001 is well-tolerated by patients with chronic obstructive pulmonary disease (COPD). The ongoing two-part Phase 2 trial, called ... Read more

June 5, 2018June 5, 2018

Add-on Treatment with Fasenra Fails to Reduce COPD Worsening in TERRANOVA Trial

News

The investigational monoclonal antibody Fasenra (benralizumab) failed to reduce exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), top-line results of the Phase 3 TERRANOVA trial ... Read more

April 6, 2018April 6, 2018

Arch Biopartners’ Therapy Candidate AB569 Receives US Patent for Treatment of Chronic Lung Infections

News

AB569, Arch Biopartners’ lead therapy candidate, has received a U.S. patent for the treatment of chronic lung infections in patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis. Patent ... Read more

Posts by: Alice Melao

Alice Melao

Verona Pharma’s Candidate RPL554 for COPD Will Be Named Ensifentrine

FDA Approves Yupelri as New Treatment for Adults with COPD

VA Researchers Working on 3D-Printed Artificial Lung for Patients with COPD, Other Pulmonary Diseases

Two Phase 2 Trials Demonstrate RPL554 Has Potential to Enhance Bronchodilators’ Efficacy in COPD

Bevespi Aerosphere Shows Similar Effectiveness as Anoro Elipta in COPD Study

Low, Moderate Psychological Distress Increases Risk of COPD, Other Diseases, Study Shows

New UK Study Recruiting Participants for Evaluation of Early COPD Risk Factors

Synairgen’s Antiviral Therapy SNG001 Proven Safe for COPD Patients in Phase 2 Trial

Add-on Treatment with Fasenra Fails to Reduce COPD Worsening in TERRANOVA Trial

Arch Biopartners’ Therapy Candidate AB569 Receives US Patent for Treatment of Chronic Lung Infections

Pin It on Pinterest